Avia Logo

Compare Products


Jump to:
Categories
Solutions
Description
Compatibility Level
Clients
Use cases
EHR integrations
Client types
Differentiators
Keywords
Media
Company details
Jump to:
Categories
Solutions
Description
Compatibility Level
Clients
Use cases
EHR integrations
Client types
Differentiators
Keywords
Media
Company details
CancerIQ
CancerIQ

0 review

DiagMMR
DiagMMR

0 review

Categories

Solutions

Description

Product Description:

Medicine is in an era of tremendous progress against cancer. From immunotherapy to multi-cancer early detection tests, we’ve never had better tools to fight disease. Yet people are being diagnosed at earlier ages and later cancer stages, and disparities in cancer outcomes persist. That’s because the traditional, one-size-fits-all approach to cancer prevention and early detection allows patients to fall through the cracks.

CancerIQ is the only platform that makes it possible to start, run and grow a cancer genetics program across broad populations. Integrated directly into real-time EHR workflows, CancerIQ makes it easy to gather comprehensive patient data, automatically map it to the latest evidence-based guidelines, and expand access to personalized care plans, genomic innovations, and cutting-edge clinical solutions.

Feature Highlights

  • Comprehensive Risk Assessment. Close gaps in care with comprehensive, population-level risk assessment based on family history, lifestyle choices and screening adherence 
  • Point-of-care Decision Guidance. Engage, educate and navigate patients through hyper-personalized care pathways based on individual and genetic risk factors 
  • Proven Near-Term ROI. Gain insight into program performance and opportunities for continued improvement and growth.

Testimonials

 

“We’ve seen how the right clinical decision support technology can transform precision medicine, and now we’re poised to see that happen in precision prevention. CancerIQ not only collects family history and genetic information, but it translates it into real-time, actionable, evidence-based alerts, which significantly reduces the burden on our clinical and IT teams. We expect this will help us scale our cancer control efforts, reduce variability in care, and ultimately improve patient outcomes.” — Dr. James L. Weese, FACS, Vice President, Aurora Cancer Care, Advocate Aurora Health "Through our partnership with CancerIQ, we’ve been able to scale a small grassroots genetic testing program into a system-wide initiative to help our primary care providers get ahead of cancer. CancerIQ’s seamless integration with the EMR and high-touch customer success team has not only taken the burden off our IT teams and support staff, but made our health system truly stand out against competitors." — Dr. Candace Westgate, Medical Director, Adventist Health AHEAD Program "There's really no other platform that can help us do what we're trying to do here in our breast center to manage and navigate our high-risk breast patients – our key stakeholders all see the value in it, too. The CancerIQ questionnaire for patients has been a big game changer in that it addresses a much more comprehensive set of genetic, hereditary, and lifestyle risk factors for these women." — Leah Marcantel, RN, Nurse Navigator OCN CN-BN, CGRA, Christus Ochsner Health Southwestern Louisiana “My role is to take the best in clinical practice and roll it out at scale. The providers in our organization are responsible for implementing a wide range of care transformation initiatives, and the CancerIQ SMART on FHIR app makes it easy. Primary care practitioners are responsible for multiple quality, maintenance and preventative care measures, and cancer is the one where we have the potential to make the most impact. That’s why we’re taking advantage of CancerIQ analytics to quantify our work and continuously do better and better.”

— Dr. Rakhal Reddy, System Medical Director of Health Informatics, Adventist Health "As a genetic counselor you want to be able to work with those patients that have a personal or family history of cancer that are getting a referral. But, there are just so many patients out there that are not getting that opportunity. CancerIQ is not only helping me in my everyday job to reduce my administrative workload and reduce the burnout of my staff, but it's also helping us as an organization find more at-risk patients." — Ashley Navarro, MS, CGC, Genetic Counseling Manager & Certified Genetic Counselor, Dignity Health Cancer Institute

About CancerIQ, Inc:

CancerIQ is the only platform that makes it possible to start, run and grow a cancer genetics program across broad populations. Integrated directly into real-time EHR workflows, CancerIQ makes it easy to gather comprehensive patient data, automatically map it to the latest evidence-based guidelines, and expand access to personalized care plans, genomic innovations, and cutting-edge clinical solutions.

Product Description:

DiagMMR is designed to be a predictive diagnostic tool that enables preventive follow-up and counselling for affected mutation carriers who are at high risk for developing Lynch syndrome related cancers.

While current Lynch syndrome diagnosis relies heavily on tumor studies, the quantitative DiagMMR method allows carrier diagnosis based on a minimally invasive tissue sample before the person has developed any cancer, without the knowledge and details of an inherited mutation.

The inherent challenges to variant interpretation in genetic testing can be avoided and the conclusive and actionable results removes the burden of uncertainty from both the patients and the treating medical professionals.

About LS CancerDiag:
LS CancerDiag Ltd is committed to reducing cancer mortality rates with a low-cost, simple diagnostic method that detects an inherited cancer-causing condition prior to cancer. Their vision is to see DiagMMR™ as a new global testing standard in LS diagnostics. Lynch syndrome is the main cause of hereditary colorectal cancers and it also causes a broad spectrum of other tumors. With a significant proportion of the world’s population carrying the Lynch syndrome mutation, there are potentially tens of millions under a severe risk for being affected by LS. Their groundbreaking DiagMMR™ assay is an easy functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome (previously known as Hereditary Non­Polyposis Colorectal Cancer; HNPCC). Their mission is to save lives through an innovation that dramatically simplifies diagnostics of Lynch syndrome by delivering predictive and accurate results with a fast, unique and cost-efficient method globally.

Compatibility level

Select which hospital or health system you work at and see a personalized compatibility level.

Clients

Select which hospital or health system you work at and see the client list

Use Cases

Description:

None provided

Pediatric use cases:

None provided

Users:

None provided

Description:

LYNCH SYNDROME

1 in 279 people have Lynch syndrome, i.e. inherited mismatch repair (MMR) deficiency, making it the most common cause of hereditary cancers.

INHERITED DEFECT

Lynch syndrome (LS) is inherited with 50% probability within affected families. Each single year, more than 2 million new cancer cases should be tested for LS.

INDIVIDUAL RISK

Individuals with inherited MMR deficiency have an up to 80% risk of developing cancer and at a significantly younger age than the general population.

INNOVATIVE SOLUTION

DiagMMR is a simple and accurate test to reliably detect MMR deficiency, supporting the early detection of Lynch syndrome, enabling preventive care and helping save lives.

Pediatric use cases:

None provided

Users:

Not specified

EHR Integrations

Integrations:

Ambulatory EMR, Ancillary EMR, Pop health platform

EMR Integration & Relevant Hardware:

None provided

EMRs Supported:

Epic, Cerner, Allscripts, Meditech, Athenahealth

Hardware Compatibility:

None provided

Integrations:

None provided

EMR Integration & Relevant Hardware:

None provided

EMRs Supported:

None provided

Hardware Compatibility:

None provided

Client Types

None provided

Differentiators

Differentiators vs EHR Functionality:

None provided

Differentiators vs Competitors:

None provided

Differentiators vs EHR Functionality:

None provided

Differentiators vs Competitors:

None provided

Keywords

Images

No images provided

No images provided

Videos

1 of 1

AboutCancerIQ-Genetics.mov

1 of 1

edit-media

Downloads

No content provided

Alternatives

Company Details

Founded in 2013

Founded in 2013

team illustration
Share your product comparison with your collegues.

Need help narrowing down products?

Add more criteria to see your compatibility level for every vendor. It only takes a few minutes, just create a free account to get started.
back to top